Pleural mesothelioma (PM) exhibits altered lipid metabolism and NFκB dysregulation, driven by FABP5, promoting tumor growth and inflammation. Silencing FABP5 alters cell dynamics, suggesting it as a potential therapeutic target in PM.
- Eleonora Vecchio
- Raffaella Gallo
- Giuseppe Fiume